Non-small cell lung cancer individuals whove already received one prior chemotherapy regimen.

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and increases progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer individuals who’ve already received one prior chemotherapy regimen, regarding to analyze presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology . This symposium is sponsored by the American Society of Clinical Oncology , the American Culture for Radiation Oncology , the International Association for the Study of Lung Malignancy and The University of Chicago. Docetaxel is the standard second-range treatment for stage IIIB and stage IV NS-NSCLC patients.

Economy. Put into previous evidence, the new results suggest that ‘addressing worker mental health increases worker productivity at work [with] the prospect of a positive return-on-expense from an employer’s perspective,’ Dr. Hilton and colleagues conclude. However, they remember that employers may need to wait around for treatment to work before they start to see the results in terms of increased productivity.. Addressing worker mental health issues increases productivity: Researches Effective treatment for employee mental health problems leads to significant improvements in productivity, according to a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine .